Insider Trading activities of Bellicum Pharmaceuticals, Inc (BLCM)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bellicum Pharmaceuticals, Inc (BLCM) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bellicum Pharmaceuticals, Inc since year 2005. Table 2 shows the detailed insider transactions of Bellicum Pharmaceuticals, Inc since 2005. The reporting company's ticker symbol is BLCM. The reporting company's CIK number is 1358403.
The total value of stock buying since 2005 is $2,125,195.
The total value of stock sales since 2005 is $18,409,405.
The total value of stock option exercises since 2005 is $580,797.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Bellicum Pharmaceuticals, Inc (BLCM).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-09 40,000 $50,000 0 $0 0 $0
2019-08 28,000 $29,604 0 $0 0 $0
2019-01 0 $0 0 $0 12,062 $0
2018-11 10,000 $45,599 0 $0 0 $0
2018-09 0 $0 10,000 $70,410 0 $0
2018-07 0 $0 40,000 $305,120 0 $0
2018-05 0 $0 6,206 $49,468 0 $0
2018-01 0 $0 881,222 $7,224,682 6,564 $0
2017-12 0 $0 17,117 $159,667 0 $0
2017-11 0 $0 6,206 $61,383 0 $0
2017-07 0 $0 24,260 $290,046 13,823 $35,248
2017-05 0 $0 6,311 $77,252 0 $0
2017-03 166,666 $1,999,992 0 $0 0 $0
2017-02 0 $0 30,000 $376,230 0 $0
2016-12 0 $0 45,000 $763,530 0 $0
2016-11 0 $0 29,300 $578,361 0 $0
2016-09 0 $0 61,000 $1,222,057 14,000 $104,580
2016-08 0 $0 69,000 $1,355,813 1,000 $7,470
2016-07 0 $0 50,000 $718,717 0 $0
2016-06 0 $0 40,000 $520,000 40,000 $101,999
2016-04 0 $0 55,000 $636,845 0 $0
2016-01 0 $0 35,000 $681,905 35,000 $89,250
2015-12 0 $0 5,000 $114,740 5,000 $12,750
2015-11 0 $0 68,300 $1,344,978 15,000 $38,250
2015-10 0 $0 2,500 $36,442 0 $0
2015-09 0 $0 7,500 $136,942 5,000 $12,750
2015-08 0 $0 2,500 $50,607 0 $0
2015-07 0 $0 56,000 $1,168,050 70,000 $178,500
2015-06 0 $0 20,000 $466,160 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Bellicum Pharmaceuticals, Inc insiders (BLCM)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-09-10 Fair Richard A. (President and CEO) Buy 40,000 1.25 50,000
2019-08-29 Ward Shane (Sr. VP and General Counsel) Buy 8,000 1.23 9,824
2019-08-21 Fair Richard A. (President and CEO) Buy 20,000 .99 19,780
2019-01-03 Williams Rosemary Y. (Principal Accounting Officer) Option Ex 782 .00 0
2019-01-03 Smith Alan K. (EVP, Technical Operations) Option Ex 1,562 .00 0
2019-01-03 Spencer David M. (Chief Technology Officer) Option Ex 1,562 .00 0
2019-01-02 Williams Rosemary Y. (Principal Accounting Officer) Option Ex 1,281 .00 0
2019-01-02 Naeve Gregory S. (Chief Business Officer) Option Ex 2,031 .00 0
2019-01-02 Smith Alan K. (EVP, Technical Operations) Option Ex 2,344 .00 0
2019-01-02 Spencer David M. (Chief Technology Officer) Option Ex 2,500 .00 0
2018-11-09 Stonehouse Jon P Buy 10,000 4.56 45,599
2018-09-04 Spencer David M. (Chief Technology Officer) Sale 10,000 7.04 70,410
2018-07-18 Spencer David M. (Chief Technology Officer) Sale 40,000 7.63 305,120
2018-05-25 Musso Alan A (CFO and Treasurer) Sale 6,206 7.97 49,468
2018-01-19 Baker Julian (10% Owner) Sale 295,361 7.91 2,336,305
2018-01-18 Baker Julian (10% Owner) Sale 324,774 8.12 2,635,865
2018-01-17 Baker Julian (10% Owner) Sale 260,600 8.63 2,247,935
2018-01-09 Smith Alan K. (EVP, Technical Operations) Sale 487 9.40 4,577
2018-01-03 Smith Alan K. (EVP, Technical Operations) Option Ex 1,563 .00 0
2018-01-03 Spencer David M. (Chief Scientific Officer) Option Ex 1,563 .00 0
2018-01-03 Moseley Ken (Sr. VP and General Counsel) Option Ex 1,563 .00 0
2018-01-03 Musso Alan A (CFO and Treasurer) Option Ex 1,875 .00 0
2017-12-11 Musso Alan A (CFO and Treasurer) Sale 17,117 9.33 159,667
2017-11-27 Musso Alan A (CFO and Treasurer) Sale 6,206 9.89 61,383
2017-07-24 Smith Alan K. (EVP, Technical Operations) Sale 437 11.85 5,178
2017-07-13 Moseley Ken (Sr. VP and General Counsel) Sale 13,823 12.26 169,469
2017-07-13 Moseley Ken (Sr. VP and General Counsel) Option Ex 13,823 2.55 35,248
2017-07-10 Spencer David M. (Chief Scientific Officer) Sale 10,000 11.54 115,399
2017-05-25 Musso Alan A (CFO and Treasurer) Sale 6,311 12.24 77,252
2017-03-24 Baker Bros. Advisors (gp) Llc (10% Owner) Buy 166,666 12.00 1,999,992
2017-02-07 Slawin Kevin M. Sale 30,000 12.54 376,230
2016-12-15 Slawin Kevin M. (Chief Technology Officer) Sale 30,000 15.45 463,530
2016-12-05 Spencer David M. (Chief Scientific Officer) Sale 10,000 20.00 200,000
2016-11-28 Musso Alan A (CFO and Treasurer) Sale 23,027 19.54 449,878
2016-11-25 Musso Alan A (CFO and Treasurer) Sale 6,273 20.48 128,483
2016-09-23 Spencer David M. (Chief Scientific Officer) Sale 6,200 20.19 125,171
2016-09-23 Moseley Ken (Sr. VP and General Counsel) Sale 11,700 20.10 235,193
2016-09-23 Moseley Ken (Sr. VP and General Counsel) Option Ex 11,700 7.47 87,399
2016-09-23 Slawin Kevin M. (Chief Technology Officer) Sale 23,216 20.12 467,082
2016-09-22 Spencer David M. (Chief Scientific Officer) Sale 10,000 19.68 196,830
2016-09-21 Spencer David M. (Chief Scientific Officer) Sale 300 20.04 6,012
2016-09-21 Moseley Ken (Sr. VP and General Counsel) Sale 100 20.04 2,004
2016-09-21 Moseley Ken (Sr. VP and General Counsel) Option Ex 100 7.47 747
2016-09-21 Slawin Kevin M. (Chief Technology Officer) Sale 200 20.04 4,008
2016-09-20 Spencer David M. (Chief Scientific Officer) Sale 100 20.00 2,000
2016-09-20 Moseley Ken (Sr. VP and General Counsel) Sale 200 20.00 4,000
2016-09-20 Moseley Ken (Sr. VP and General Counsel) Option Ex 200 7.47 1,494
2016-09-20 Slawin Kevin M. (Chief Technology Officer) Sale 400 20.00 8,000
2016-09-19 Spencer David M. (Chief Scientific Officer) Sale 700 20.02 14,013
2016-09-19 Moseley Ken (Sr. VP and General Counsel) Sale 1,300 20.01 26,018
2016-09-19 Moseley Ken (Sr. VP and General Counsel) Option Ex 1,300 7.47 9,711
2016-09-19 Slawin Kevin M. (Chief Technology Officer) Sale 2,606 20.01 52,151
2016-09-16 Spencer David M. (Chief Scientific Officer) Sale 1,700 20.01 34,015
2016-09-16 Moseley Ken (Sr. VP and General Counsel) Sale 700 20.00 14,000
2016-09-16 Moseley Ken (Sr. VP and General Counsel) Option Ex 700 7.47 5,229
2016-09-16 Slawin Kevin M. (Chief Technology Officer) Sale 1,578 20.00 31,560
2016-08-15 Spencer David M. (Chief Scientific Officer) Sale 1,000 20.00 20,000
2016-08-15 Moseley Ken (Sr. VP and General Counsel) Sale 1,000 20.00 20,000
2016-08-15 Moseley Ken (Sr. VP and General Counsel) Option Ex 1,000 7.47 7,470
2016-08-15 Slawin Kevin M. (Chief Technology Officer) Sale 67,000 19.64 1,315,813
2016-07-27 Spencer David M. (Chief Scientific Officer) Sale 10,000 15.00 150,000
2016-07-27 Slawin Kevin M. (Chief Technology Officer) Sale 15,000 15.00 225,000
2016-07-18 Slawin Kevin M. (Chief Technology Officer) Sale 2,719 13.99 38,044
2016-07-15 Slawin Kevin M. (Chief Technology Officer) Sale 22,281 13.72 305,673
2016-06-02 Moseley Ken (Sr. VP and General Counsel) Sale 15,000 13.00 195,000
2016-06-02 Moseley Ken (Sr. VP and General Counsel) Option Ex 15,000 2.55 38,250
2016-06-02 Moseley Annemarie (COO/EVP Clinical Development) Sale 25,000 13.00 325,000
2016-06-02 Moseley Annemarie (COO/EVP Clinical Development) Option Ex 25,000 2.55 63,749
2016-04-22 Slawin Kevin M. (Chief Technology Officer) Sale 55,000 11.58 636,845
2016-01-04 Moseley Annemarie (COO/EVP Clinical Development) Sale 35,000 19.48 681,905
2016-01-04 Moseley Annemarie (COO/EVP Clinical Development) Option Ex 35,000 2.55 89,250
2015-12-14 Spencer David M. (Chief Scientific Officer) Option Ex 5,000 2.55 12,750
2015-12-01 Spencer David M. (Chief Scientific Officer) Sale 5,000 22.95 114,740
2015-11-24 Musso Alan A (CFO and Treasurer) Sale 29,300 22.34 654,474
2015-11-16 Slawin Kevin M. (Chief Technology Officer) Sale 24,000 20.65 495,504
2015-11-02 Moseley Ken (Sr. VP and General Counsel) Sale 15,000 13.00 195,000
2015-11-02 Moseley Ken (Sr. VP and General Counsel) Option Ex 15,000 2.55 38,250
2015-10-01 Farrell Thomas J. (President and CEO) Sale 2,500 14.58 36,442
2015-09-21 Spencer David M. (Chief Scientific Officer) Option Ex 5,000 2.55 12,750
2015-09-11 Spencer David M. (Chief Scientific Officer) Sale 5,000 19.00 95,000
2015-09-01 Farrell Thomas J. (President and CEO) Sale 2,500 16.78 41,942
2015-08-03 Farrell Thomas J. (President and CEO) Sale 2,500 20.24 50,607
2015-07-15 Slawin Kevin M. (Chief Technology Officer) Sale 6,000 20.00 120,000
2015-07-02 Spencer David M. (Chief Scientific Officer) Option Ex 20,000 2.55 51,000
2015-07-01 Moseley Ken (Sr. VP and General Counsel) Sale 15,000 20.96 314,415
2015-07-01 Moseley Ken (Sr. VP and General Counsel) Option Ex 15,000 2.55 38,250
2015-07-01 Moseley Annemarie (COO/EVP Clinical Development) Sale 35,000 20.96 733,635
2015-07-01 Moseley Annemarie (COO/EVP Clinical Development) Option Ex 35,000 2.55 89,250
2015-06-16 Spencer David M. (Chief Scientific Officer) Sale 20,000 23.31 466,160

Insider trading activities including stock purchases, stock sales, and option exercises of BLCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bellicum Pharmaceuticals, Inc (symbol BLCM, CIK number 1358403) see the Securities and Exchange Commission (SEC) website.




Real-time Insider Trading

Insider Officer Cluster Trading

Top Officer Buys of the Week

Top Officer Buys of the Month